Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery
Authors
Wilson, M. R.Eyre, T. A.
Martinez-Calle, N.
Ahearne, M.
Parsons, K. E.
Preston, G.
Khwaja, J.
Schofield, J.
Elliot, Johnathon
Mula Kh, A.
Shah, N.
Cheung, C. K.
Timmins, M. A.
Creasey, T.
Linton, Kim M
Smith, J.
Fox, C. P.
Miall, F.
Cwynarski, K.
McKay, P.
Affiliation
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.Issue Date
2020
Metadata
Show full item recordAbstract
High-dose methotrexate (HD-MTX) is increasingly used as prophylaxis for patients with diffuse large B-cell lymphoma (DLBCL) at high risk of central nervous system (CNS) relapse. However, there is limited evidence to guide whether to intercalate HD-MTX (i-HD-MTX) between R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone given at 21-day intervals) or to give it at the end of treatment (EOT) with R-CHOP-21. We conducted a retrospective, multicenter analysis of 334 patients with DLBCL who received CNS prophylaxis with i-HD-MTX (n = 204) or EOT HD-MTX (n = 130). Primary end points were R-CHOP delay rates and HD-MTX toxicity. Secondary end points were CNS relapse rate, progression-free survival, and overall survival. The EOT group had more patients with a high CNS international prognostic index (58% vs 39%; P < .001) and more concurrent intrathecal prophylaxis (56% vs 34%; P < .001). Of the 409 cycles of i-HD-MTX given, 82 (20%) were associated with a delay of next R-CHOP (median, 7 days). Delays were significantly increased when i-HD-MTX was given after day 9 post-R-CHOP (26% vs 16%; P = .01). On multivariable analysis, i-HD-MTX was independently associated with increased R-CHOP delays. Increased mucositis, febrile neutropenia, and longer median inpatient stay were recorded with i-HD-MTX delivery. Three-year cumulative CNS relapse incidence was 5.9%, with no differences between groups. There was no difference in survival between groups. We report increased toxicity and R-CHOP delay with i-HD-MTX compared with EOT delivery but no difference in CNS relapse or survival. Decisions on HD-MTX timing should be individualized and, where i-HD-MTX is favored, we recommend scheduling before day 10 of R-CHOP cycles.Citation
Wilson MR, Eyre TA, Martinez-Calle N, Ahearne M, Parsons KE, Preston G, et al. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery. Blood Advances. 2020;4(15):3586-93.Journal
Blood AdvancesDOI
10.1182/bloodadvances.2020002421PubMed ID
32761231Additional Links
https://dx.doi.org/10.1182/bloodadvances.2020002421Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/bloodadvances.2020002421
Scopus Count
Collections
Related articles
- Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
- Authors: Wilson MR, Eyre TA, Kirkwood AA, Wong Doo N, Soussain C, Choquet S, Martinez-Calle N, Preston G, Ahearne M, Schorb E, Moles-Moreau MP, Ku M, Rusconi C, Khwaja J, Narkhede M, Lewis KL, Calimeri T, Durot E, Renaud L, Øvlisen AK, McIlroy G, Ebsworth TJ, Elliot J, Santarsieri A, Ricard L, Shah N, Liu Q, Zayac AS, Vassallo F, Lebras L, Roulin L, Lombion N, Manos K, Fernandez R, Hamad N, Lopez-Garcia A, O'Mahony D, Gounder P, Forgeard N, Lees C, Agbetiafa K, Strüßmann T, Htut TW, Clavert A, Scott H, Guidetti A, Barlow BR, Tchernonog E, Smith J, Miall F, Fox CP, Cheah CY, El Galaly TC, Ferreri AJM, Cwynarski K, McKay P
- Issue date: 2022 Apr 21
- New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
- Authors: Cai QQ, Hu LY, Geng QR, Chen J, Lu ZH, Rao HL, Liu Q, Jiang WQ, Huang HQ, Lin TY, Xia ZJ
- Issue date: 2016 Sep 13
- Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis.
- Authors: Jeong H, Cho H, Kim H, Chae H, Lee JB, Lee K, Kim S, Lee SW, Ryu JS, Kim KW, Chae EJ, Huh J, Park CS, Yoon DH, Suh C
- Issue date: 2021 Apr 27
- Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: a systematic review and meta-analysis.
- Authors: Tolley ER, Lewinter C, Pedersen LM, Nielsen TH
- Issue date: 2024 Oct 1
- Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse.
- Authors: Bobillo S, Joffe E, Sermer D, Mondello P, Ghione P, Caron PC, Hamilton A, Hamlin PA, Horwitz SM, Kumar A, Matasar MJ, Batlevi CL, Moskowitz A, Noy A, Owens CN, Palomba ML, Straus D, von Keudell G, Dogan A, Zelenetz AD, Seshan VE, Younes A
- Issue date: 2021 Jun 16